logo
  

Why NeuroSense Therapeutics Is Rising In Pre-market?

NeuroSense Therapeutics Ltd. (NRSN) reported results from a biomarker study conducted to evaluate the potential of CogniC, the company's combination drug for the treatment of Alzheimer's disease. The company said the biomarker study identified several biomarkers associated with AD, which indicate CogniC's mechanism of action may be effective in targeting the pathways involved in the disease.

"Having identified these promising biomarkers, which have the potential to be modulated by CogniC, we are now preparing to carry out a clinical proof-of-concept study in conjunction with a leading AD clinic. The study is expected to commence in 2023," said CEO, Alon Ben-Noon.

Shares of NeuroSense Therapeutics are up 62% in pre-market trade on Thursday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing company Lyft announced its foray into the media and advertisement business with the launch of Lyft Media as part of its vision to build the world's largest transportation media network. Lyft Media has built a suite of new products to allow advertisers to engage with Lyft's growing audience throughout their transportation journeys. Sysco Corp. (SYY) Tuesday reported a more than a three-times surge in fourth-quarter earnings, supported by 17.5 percent growth in sales. The company projects fiscal 2023 adjusted earnings to grow. Earnings for the quarter spiked to $509.99 million from $151.09 million last year. On a per share basis,... Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22.
RELATED NEWS
Follow RTT